[Switching and combining strategies of antidepressant medications].
Fiche publication
Date publication
mars 2016
Journal
Presse medicale (Paris, France : 1983)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr HAFFEN Emmanuel
Tous les auteurs :
Charpeaud T, Moliere F, Bubrovszky M, Haesebaert F, Allaïli N, Bation R, Nieto I, Richieri R, Saba G, Bellivier F, Bennabi D, Holtzmann J, Camus V, Courtet P, Courvoisier P, d'Amato T, Doumy O, Garnier M, Bougerol T, Lançon C, Haffen E, Leboyer M, Llorca PM, Vaiva G, El-Hage W, Aouizerate B
Lien Pubmed
Résumé
Switching antidepressant medication may be helpful in depressed patients having no benefit from the initial antidepressant treatment. Before considering switching strategy, the initial antidepressant treatment should produce no therapeutic effect after at least 4 weeks of administration at adequate dosage. Choosing an antidepressant of pharmacologically distinct profile fails to consistently demonstrate a significant superiority in terms of effectiveness over the switching to another antidepressant within the same pharmacological class. Augmenting SSRI/SNRIs with mirtazapine/mianserin has become the most recommended strategy of antidepressant combinations. Augmenting SSRI with tricyclic drugs is now a less recommended strategy of antidepressant combinations given the increased risk for the occurrence of pharmacokinetic drug-drug interactions and adverse effects.
Mots clés
Antidepressive Agents, adverse effects, Depressive Disorder, drug therapy, Drug Administration Schedule, Drug Interactions, Drug Resistance, Drug Substitution, Drug Therapy, Combination, Humans, Practice Guidelines as Topic
Référence
Presse Med. 2016 Mar;45(3):329-37